Biogen names new chairman as William Young retires

Biogen Idec (BIIB) has named director Stelios Papadopoulos as chairman to replace William Young, who will retire at the biotech company's next annual shareholders meeting.

Papadopoulos is Chairman of Exelixis (EXEL), a cancer-drug discovery company that he co-founded in 1994, and Regulus Therapeutics (RGLS).

ISI analyst Mark Schoenebaum seems to be very happy about Papadopoulos' appointment. "Stelios has as much, if not more, experience than anyone on Planet Earth right now advising biotech companies on how to create shareholder value," Schoenebaum says. "If the world of biotech was a city, Stelios would be mayor." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs